Nifekalant
Chemical compound
- none
- In general: ℞ (Prescription only)
- 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
- 130636-43-0 Y
- 4486
- 4331
- 5VZ7GZM43E
- DTXSID7048374
- Interactive image
- Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O
InChI
- InChI=1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3
- Key:OEBPANQZQGQPHF-UHFFFAOYSA-N
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1] It has the brand name Shinbit.
References
- ^ Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.
- v
- t
- e
Ion channel modulators
VGKCsTooltip Voltage-gated potassium channels |
| ||||
---|---|---|---|---|---|
IRKsTooltip Inwardly rectifying potassium channel |
| ||||
KCaTooltip Calcium-activated potassium channel |
| ||||
K2PsTooltip Tandem pore domain potassium channel |
|
VGSCsTooltip Voltage-gated sodium channels |
| ||||
---|---|---|---|---|---|
ENaCTooltip Epithelial sodium channel |
| ||||
ASICsTooltip Acid-sensing ion channel |
|
CaCCsTooltip Calcium-activated chloride channel |
| ||||
---|---|---|---|---|---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator |
| ||||
Unsorted |
|
TRPsTooltip Transient receptor potential channels |
|
---|---|
LGICsTooltip Ligand gated ion channels |
|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e